Industry Biopharmaceuticals Products GL-ONC1, V-VET1 Website www.genelux.com Founded 2001 | Number of locations 3 (USA (2), Germany) Number of employees ~16 Headquarters San Diego Type of business Private | |
 | ||
Genelux Corporation is a privately held, biopharmaceutical clinical stage company that was founded in 2001. The main focus of Genelux is oncolytic immunotherapy based on attenuated, genetically engineered oncolytic viruses as therapeutic agent.
Contents
In 2013 Genelux obtained the San Diego Business Journal Innovation Award in the category for Medical Research.
Locations
Genelux Corp. is headquartered in San Diego, California with offices in Redlands, California, and additional operations located in Bernried, Germany.
Lead Compound
Genelux’ lead oncology compound is GL-ONC1, an attenuated vaccinia virus strain. In November 2013 GL-ONC1 has been selected as one of the "Top 10 Oncology Projects to Watch" by Elsevier Business Intelligence. Currently, GL-ONC1 is being evaluated in human clinical Phase I/II studies. In those studies GL-ONC1 was shown to be well tolerated and evidence of tumor colonization and indications for therapeutic efficacy were observed.
Veterinary Lead Compound
In addition to GL-ONC1, Genelux sponsors a veterinary trial in dogs with cancer that is conducted at the CVS Angel Care Cancer Center in Carlsbad, California. The dogs are treated with V-VET1, a non-genetically modified vaccinia virus isolate (laboratory name LIVP6.1.1) with an inactive thymidine kinase gene.
Pipeline
The preclinical pipeline of Genelux includes numerous genetically modified vaccinia virus strains with transgenes encoding for reporter proteins for deep tissue imaging, angiogenesis modifying proteins, radiosensitzing proteins, prodrug converting enzymes, biomarkers and immunomodulatory proteins.